Foghorn Therapeutics (NASDAQ:FHTX) Announces Quarterly Earnings Results

Posted by George Bondi on Aug 8th, 2026

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.14, Zacks reports. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $6.80 million.

Foghorn Therapeutics Price Performance

Shares of Foghorn Therapeutics stock opened at $6.07 on Friday. The business has a fifty day simple moving average of $4.73 and a two-hundred day simple moving average of $4.97. Foghorn Therapeutics has a 1 year low of $3.27 and a 1 year high of $6.95. The company has a market capitalization of $356.37 million, a price-to-earnings ratio of -6.19 and a beta of 2.89.

Institutional Trading of Foghorn Therapeutics

Hedge funds have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in shares of Foghorn Therapeutics during the fourth quarter worth approximately $130,000. Public Employees Retirement System of Ohio increased its stake in shares of Foghorn Therapeutics by 350.3% during the fourth quarter. Public Employees Retirement System of Ohio now owns 14,269 shares of the company’s stock worth $77,000 after purchasing an additional 11,100 shares during the period. Bank of America Corp DE increased its stake in shares of Foghorn Therapeutics by 31.3% during the second quarter. Bank of America Corp DE now owns 31,297 shares of the company’s stock worth $147,000 after purchasing an additional 7,462 shares during the period. Jane Street Group LLC acquired a new stake in Foghorn Therapeutics during the 2nd quarter worth approximately $102,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Foghorn Therapeutics by 18.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,908 shares of the company’s stock valued at $84,000 after purchasing an additional 2,812 shares during the period. Institutional investors and hedge funds own 61.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on FHTX. Wall Street Zen upgraded Foghorn Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.43.

View Our Latest Stock Analysis on Foghorn Therapeutics

About Foghorn Therapeutics

(Get Free Report)

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.